News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actelion Ltd. Board Nominees Deny Sale is Main Aim
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - A group of prospective Actelion board members denied speculation they planned to prepare Europe's biggest biotech for sale and said they wanted instead to overhaul it.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
September 15, 2025
·
2 min read
·
Tristan Manalac
IPO
UPDATE: Neuroscience Biotech LB Pulls Off Upsized $285M IPO
September 11, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
Mergers & Acquisitions
Hectic Markets, Emotions Lead Biotechs To Tack On CVRs
September 10, 2025
·
6 min read
·
Annalee Armstrong
